Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase

Hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with a high mortality rate. Cisplatin (CDDP) is a widely applied anti-cancer drug. However, a large population of liver cancer patients developed CDDP resistance. The polypyrimidine tract binding protein (PTBP1) is an RNA-binding pr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tian Ruimin, Li Yanfei, Shen Xiaojie, Li Ying
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	De Gruyter 2023-09-01
Edice:	Open Medicine
Témata:	hepatocellular carcinoma ptbp1 rna-binding protein glutamine metabolism glutaminase chemosensitivity cddp resistance
On-line přístup:	https://doi.org/10.1515/med-2023-0756
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!